{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:40:08Z","timestamp":1792798808272,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"DOI":"10.1007\/s10554-026-03852-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:26:28Z","timestamp":1792751188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloid-targeted PET after negative or low-grade bone scintigraphy for cardiac amyloidosis: a systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-8858","authenticated-orcid":false,"given":"Agostino","family":"Chiaravalloti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4125-2206","authenticated-orcid":false,"given":"Daniele","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"3852_CR1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42:1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"3852_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076\u20131084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073","journal-title":"J Am Coll Cardiol"},{"key":"3852_CR3","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"3852_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S et al (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2014evidence base and standardized methods of imaging. J Nucl Cardiol 26:2065\u20132123. https:\/\/doi.org\/10.1007\/s12350-019-01760-6","journal-title":"J Nucl Cardiol"},{"key":"3852_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","volume":"27","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Ando Y, Bokhari S et al (2020) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2\u2014diagnostic criteria and appropriate utilization. J Nucl Cardiol 27:659\u2013673. https:\/\/doi.org\/10.1007\/s12350-019-01761-5","journal-title":"J Nucl Cardiol"},{"key":"3852_CR6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3852_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","volume":"319","author":"MDF McInnes","year":"2018","unstructured":"McInnes MDF, Moher D, Thombs BD et al (2018) Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA statement. JAMA 319:388\u2013396. https:\/\/doi.org\/10.1001\/jama.2017.19163","journal-title":"JAMA"},{"key":"3852_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529\u2013536. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"3852_CR9","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.7326\/M21-2234","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, Mallett S, Takwoingi Y et al (2021) QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies. Ann Intern Med 174:1592\u20131599. https:\/\/doi.org\/10.7326\/M21-2234","journal-title":"Ann Intern Med"},{"key":"3852_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","volume":"31","author":"L Lin","year":"2020","unstructured":"Lin L, Chu H (2020) Meta-analysis of proportions using generalized linear mixed models. Epidemiology 31:713\u2013717. https:\/\/doi.org\/10.1097\/EDE.0000000000001232","journal-title":"Epidemiology"},{"key":"3852_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","volume":"25","author":"B Pilebro","year":"2018","unstructured":"Pilebro B, Arvidsson S, Lindqvist P, Sundstr\u00f6m T, Westermark P, Antoni G, Suhr O, S\u00f6rensen J (2018) Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol 25:240\u2013248. https:\/\/doi.org\/10.1007\/s12350-016-0638-5","journal-title":"J Nucl Cardiol"},{"key":"3852_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, Ihne S, Brumberg J et al (2019) Detection of cardiac amyloidosis with 18F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging 46:1407\u20131416. https:\/\/doi.org\/10.1007\/s00259-019-04290-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3852_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","volume":"27","author":"K Takasone","year":"2020","unstructured":"Takasone K, Katoh N, Takahashi Y, Abe R, Ezawa N, Yoshinaga T, Yanagisawa S, Yazaki M, Oguchi K, Koyama J, Sekijima Y (2020) Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11\u00a0C-Pittsburgh compound B PET imaging. Amyloid 27:266\u2013274. https:\/\/doi.org\/10.1080\/13506129.2020.1798223","journal-title":"Amyloid"},{"key":"3852_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","volume":"27","author":"S M\u00f6ckelind","year":"2020","unstructured":"M\u00f6ckelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundstr\u00f6m T (2020) Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid 27:191\u2013199. https:\/\/doi.org\/10.1080\/13506129.2020.1760237","journal-title":"Amyloid"},{"key":"3852_CR15","doi-asserted-by":"publisher","first-page":"693194","DOI":"10.3389\/fcvm.2021.693194","volume":"8","author":"BW Sperry","year":"2021","unstructured":"Sperry BW, Bock A, DiFilippo FP, Donnelly JP, Hanna M, Jaber WA (2021) Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis. Front Cardiovasc Med 8:693194. https:\/\/doi.org\/10.3389\/fcvm.2021.693194","journal-title":"Front Cardiovasc Med"},{"key":"3852_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","volume":"16","author":"OF Clerc","year":"2023","unstructured":"Clerc OF, Cuddy SAM, Robertson M et al (2023) Cardiac amyloid quantification using 124I-evuzamitide (124I-P5\u2009+\u200914) versus 18F-florbetapir: a pilot PET\/CT study. JACC Cardiovasc Imaging 16:1419\u20131432. https:\/\/doi.org\/10.1016\/j.jcmg.2023.07.007","journal-title":"JACC Cardiovasc Imaging"},{"key":"3852_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","volume":"18","author":"DA Smiley","year":"2025","unstructured":"Smiley DA, Einstein AJ, O\u2019Gorman KJ et al (2025) Early detection of transthyretin cardiac amyloidosis using 124I-evuzamitide positron emission tomography\/computed tomography. JACC Cardiovasc Imaging 18:799\u2013811. https:\/\/doi.org\/10.1016\/j.jcmg.2025.01.018","journal-title":"JACC Cardiovasc Imaging"},{"key":"3852_CR18","doi-asserted-by":"publisher","first-page":"1747625","DOI":"10.3389\/fnume.2026.1747625","volume":"6","author":"HSA Tingen","year":"2026","unstructured":"Tingen HSA, Stormezand GN, van Snick P et al (2026) Pittsburgh compound B positron emission tomography detects cardiomyopathy in hereditary transthyretin amyloidosis patients with negative bone scintigraphy: a pilot study. Front Nucl Med 6:1747625. https:\/\/doi.org\/10.3389\/fnume.2026.1747625","journal-title":"Front Nucl Med"},{"key":"3852_CR19","doi-asserted-by":"publisher","first-page":"102707","DOI":"10.1016\/j.nuclcard.2026.102707","volume":"60","author":"OF Clerc","year":"2026","unstructured":"Clerc OF, Romero Pab\u00f3n AJ, Cuddy SAM et al (2026) Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography\/computed tomography with 124I-evuzamitide (124I-p5\u2009+\u200914, AT-01). J Nucl Cardiol 60:102707. https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102707","journal-title":"J Nucl Cardiol"},{"key":"3852_CR20","doi-asserted-by":"publisher","first-page":"16903","DOI":"10.20452\/pamw.16903","volume":"135","author":"K Holcman","year":"2025","unstructured":"Holcman K, Chmura \u0141, Rubi\u015b P, St\u0119pie\u0144 A, Graczyk K, Kostkiewicz M (2025) Glu112Lys: a rare pathogenic transthyretin gene variant associated with negative scintigraphy findings. Pol Arch Intern Med 135:16903. https:\/\/doi.org\/10.20452\/pamw.16903","journal-title":"Pol Arch Intern Med"},{"key":"3852_CR21","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1111\/ene.70057","volume":"32","author":"A Dori","year":"2025","unstructured":"Dori A, Chorin O, Ruhrman-Shahar N et al (2025) Hereditary transthyretin amyloidosis in Israel: genetic landscape and clinical characteristics. Eur J Neurol 32:e70057. https:\/\/doi.org\/10.1111\/ene.70057","journal-title":"Eur J Neurol"},{"key":"3852_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.33963\/v.phj.107207","volume":"83","author":"K Holcman","year":"2025","unstructured":"Holcman K, Rubi\u015b P, Podolec P et al (2025) Transthyretin-related amyloid cardiomyopathy: a single-center experience in southern Poland, an endemic area. Kardiol Pol 83:1039\u20131052. https:\/\/doi.org\/10.33963\/v.phj.107207","journal-title":"Kardiol Pol"},{"key":"3852_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10554-025-03436-4","volume":"41","author":"JL Ngouchet Nouhossi","year":"2025","unstructured":"Ngouchet Nouhossi JL, Minga I, Szasz T et al (2025) Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging 41:1487\u20131496. https:\/\/doi.org\/10.1007\/s10554-025-03436-4","journal-title":"Int J Cardiovasc Imaging"},{"key":"3852_CR24","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s10554-025-03493-9","volume":"41","author":"S Ers\u00f6zl\u00fc","year":"2025","unstructured":"Ers\u00f6zl\u00fc S, Foldyna B (2025) Afro-Caribbean patients with transthyretin cardiac amyloidosis: insights from the SCMR registry. Int J Cardiovasc Imaging 41:1465\u20131466. https:\/\/doi.org\/10.1007\/s10554-025-03493-9","journal-title":"Int J Cardiovasc Imaging"},{"key":"3852_CR25","doi-asserted-by":"publisher","first-page":"100292","DOI":"10.1016\/j.eanmi.2026.100292","volume":"4","author":"R S\u00e1 e Silva","year":"2026","unstructured":"S\u00e1 e Silva R, Vieira JR, Rodrigues P (2026) Understanding the [99mTc]Tc-DPD-positive spectrum in cardiac amyloidosis: clinical and prognostic insights. EANM Innov 4:100292. https:\/\/doi.org\/10.1016\/j.eanmi.2026.100292","journal-title":"EANM Innov"},{"key":"3852_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","volume":"11","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Vranian MN, Tower-Rader A et al (2018) Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. JACC Cardiovasc Imaging 11:234\u2013242. https:\/\/doi.org\/10.1016\/j.jcmg.2017.06.020","journal-title":"JACC Cardiovasc Imaging"},{"key":"3852_CR27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00259-024-06981-7","volume":"52","author":"M Zhao","year":"2025","unstructured":"Zhao M, Calabretta R, Binder P et al (2025) Clinical significance of quantitative assessment of right ventricular amyloid burden with [99mTc]Tc-DPD SPECT\/CT in transthyretin cardiac amyloidosis. Eur J Nucl Med Mol Imaging 52:1073\u20131082. https:\/\/doi.org\/10.1007\/s00259-024-06981-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3852_CR28","doi-asserted-by":"publisher","first-page":"133227","DOI":"10.1016\/j.ijcard.2025.133227","volume":"431","author":"K Holcman","year":"2025","unstructured":"Holcman K, Rubi\u015b P, \u0106miel B et al (2025) [99mTc]Tc-DPD SPECT\/CT evaluation of right and left ventricular involvement in cardiac transthyretin amyloidosis. Int J Cardiol 431:133227. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133227","journal-title":"Int J Cardiol"},{"key":"3852_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","volume":"14","author":"D Genovesi","year":"2021","unstructured":"Genovesi D, Vergaro G, Giorgetti A et al (2021) [18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging 14:246\u2013255. https:\/\/doi.org\/10.1016\/j.jcmg.2020.05.031","journal-title":"JACC Cardiovasc Imaging"},{"key":"3852_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R (2019) Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography. Ann Nucl Med 33:624\u2013628. https:\/\/doi.org\/10.1007\/s12149-019-01372-7","journal-title":"Ann Nucl Med"},{"key":"3852_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","volume":"29","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, Kessler L, Carpinteiro A et al (2022) 18F-flutemetamol positron emission tomography in cardiac amyloidosis. J Nucl Cardiol 29:779\u2013789. https:\/\/doi.org\/10.1007\/s12350-020-02363-2","journal-title":"J Nucl Cardiol"},{"key":"3852_CR32","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, Skibsted Clemmensen T, Tolbod L et al (2020) Diagnostic accuracy of [11\u00a0C]PIB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging 13:1337\u20131347. https:\/\/doi.org\/10.1016\/j.jcmg.2020.02.023","journal-title":"JACC Cardiovasc Imaging"},{"key":"3852_CR33","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1007\/s00259-026-07860-z","volume":"53","author":"T Norikane","year":"2026","unstructured":"Norikane T, Yamamoto Y, Takami Y et al (2026) Head-to-head comparison of 11\u00a0C-PiB and 18F-flutemetamol PET in transthyretin cardiac amyloidosis. Eur J Nucl Med Mol Imaging 53:4708\u20134717. https:\/\/doi.org\/10.1007\/s00259-026-07860-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3852_CR34","doi-asserted-by":"publisher","unstructured":"Dorbala S, Maurer MS, Cuddy SAM et al (2026) 124I-Evuzamitide positron emission tomography\/computed tomography for diagnosing cardiac amyloidosis: the REVEAL nonrandomized clinical trial. JAMA. Published online 30 August 2026 https:\/\/doi.org\/10.1001\/jama.2026.17361","DOI":"10.1001\/jama.2026.17361"},{"key":"3852_CR35","doi-asserted-by":"publisher","unstructured":"Masri A, Jahan I, Gillan D et al (2026) 124Iodine evuzamitide positron emission tomography in patients with established or suspected cardiac amyloidosis. https:\/\/doi.org\/10.1016\/j.jcmg.2026.08.005. JACC Cardiovasc Imaging","DOI":"10.1016\/j.jcmg.2026.08.005"},{"key":"3852_CR36","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1007\/s00259-025-07157-7","volume":"52","author":"Z Hong","year":"2025","unstructured":"Hong Z et al (2025) Enhanced diagnostic and prognostic assessment of cardiac amyloidosis using combined 11\u00a0C-PiB PET\/CT and 99mTc-DPD scintigraphy. Eur J Nucl Med Mol Imaging 52:3321\u20133332. https:\/\/doi.org\/10.1007\/s00259-025-07157-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3852_CR37","doi-asserted-by":"publisher","first-page":"102626","DOI":"10.1016\/j.jacadv.2026.102626","volume":"5","author":"T Sprauel","year":"2026","unstructured":"Sprauel T et al (2026) 18F-Florbetaben PET detection of cardiac and multi-organ involvement for identifying AL and ATTR cardiac amyloidosis. JACC Adv 5:102626. https:\/\/doi.org\/10.1016\/j.jacadv.2026.102626","journal-title":"JACC Adv"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-026-03852-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-026-03852-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-026-03852-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:54Z","timestamp":1792796634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-026-03852-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":37,"alternative-id":["3852"],"URL":"https:\/\/doi.org\/10.1007\/s10554-026-03852-0","relation":{},"ISSN":["1875-8312"],"issn-type":[{"value":"1875-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"31 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review uses published evidence and aggregate data and involves no newly recruited participants or identifiable local patient records.","order":2,"name":"Ethics","label":"Ethics approval and consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}